Myriad Genetics, Hereditary Cancer

Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced an agreement designed to enhance education and access to hereditary cancer testing for CancerCARE for Life members.
Myriad Genetics, CancerCARE for Life announce agreement
Myriad Genetics (MYGN) and INTERLINK Care Management announced an agreement designed to enhance education and access to hereditary cancer
Myriad Genetics secures patents for cancer MRD tests
SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two new patents by the United States Patent and Trademark Office,
Myriad Genetics, Inc.: Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and precision medicine, announced that the United States Patent and
Myriad Genetics, INTERLINK Partner To Enhance Access To Hereditary Cancer Testing
Myriad Genetics, Inc. (MYGN), a genetic and genomic tumor testing and precision medicine provider, and INTERLINK Care Management,
Pharmabiz1d
Myriad Genetics announces USPTO grants two new patents for its molecular residual disease assay
Myriad Genetics announces USPTO grants two new patents for its molecular residual disease assay: Salt Lake City Friday, February 7, 2025, 13:00 Hrs [IST] Myriad Genetics, Inc., a ...
Nasdaq10d
Myriad Genetics Unveils Award-Winning Research on Early Prenatal Screening Technology at SMFM Conference
Myriad Genetics, Inc. announced it will present significant research on early prenatal testing at the Society for Maternal-Fetal Medicine Conference. The study, awarded the Dru Carlson Memorial ...
manilatimes3d
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital ...
Hannah Storm breaks down latest with NBA trade deadline, Luka Doncic and more
Hannah Storm knows the NBA inside and out. As the trade deadline comes to a close, she talks through the Doncic-Davis trade.
Myriad Genetics management to meet with BTIG
Group meeting and tour of company headquarters with CEO Diaz, COO Raha and CFO Leffler in Salt Lake City, Utah on February 10 hosted by ...